Table 3. Univariable and multivariable logistic regression analyses to assess 30-day mortality among patients with E. faecium bacteremia.
| Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Male sex | 1.8 (0.8–3.8) | 0.14 | ||
| Age, per year | 1.01 (0.99–1.03) | 0.51 | ||
| Charlson, per point | 1.2 (1.1–1.4) | 0.006 | 1.2 (1.1–1.5) | 0.008 |
| Pitt bacteremia score, per point | 1.3 (1.1–1.5) | 0.003 | 1.3 (1.1–1.5) | 0.002 |
| Resistance type | 0.40 | non-significant | ||
| VSE | Reference | - | ||
| VVE | 1.9 (0.8–4.8) | 0.08 | ||
| VRE | 0.7 (0.3–1.8) | 0.14 | ||
| Source of infection | 0.33 | |||
| Other | Reference | - | ||
| Primary CLABSI | 0.6 (0.2–1.5) | 0.15 | ||
| Intra-abdominal | 1.1 (0.4–2.7) | 0.35 | ||
| Surgery/procedure | 0.2 (0.0–1.4) | 0.10 | non-significant | |
| Polymicrobial infection | 0.9 (0.4–2.0) | 0.88 | ||
| VRE-activea treatment | 0.7 (0.3–1.4) | 0.27 | ||
| Hours to effective therapy, per hour | 1.00 (0.99–1.01) | 0.67 | ||
VRE, Vancomycin-resistant enterococci; VVE, Vancomycin-variable enterococci; VSE, Vancomycin-susceptible enterococci; CLABSI, Central Line Associated Blood Stream Infection; OR, Odds Ratio; CI, Confidence Interval
aLinezolid, daptomycin, or tigecycline